Aurora Cannabis (TSE:ACB) Price Target Cut to C$4.00

Aurora Cannabis (TSE:ACBGet Rating) had its target price lowered by analysts at Cowen from C$7.00 to C$4.00 in a research note issued on Monday, BayStreet.CA reports. Cowen’s target price would suggest a potential upside of 5.82% from the stock’s current price.

A number of other research analysts also recently issued reports on the stock. ATB Capital dropped their target price on shares of Aurora Cannabis from C$5.00 to C$4.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 10th. Piper Sandler dropped their target price on shares of Aurora Cannabis from C$7.00 to C$4.00 and set a “hold” rating on the stock in a research report on Friday. CIBC lowered their price objective on shares of Aurora Cannabis from C$9.25 to C$6.50 in a report on Thursday, February 3rd. Canaccord Genuity Group reduced their target price on shares of Aurora Cannabis from C$6.00 to C$5.00 in a research note on Friday, February 11th. Finally, Stifel Nicolaus lowered their price target on shares of Aurora Cannabis from C$3.50 to C$3.00 in a report on Monday, May 2nd. Two investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. According to data from MarketBeat, Aurora Cannabis presently has an average rating of “Hold” and an average target price of C$4.53.

Shares of TSE ACB traded up C$0.13 during midday trading on Monday, reaching C$3.78. The stock had a trading volume of 1,632,858 shares, compared to its average volume of 1,860,325. The firm has a market cap of C$811.84 million and a price-to-earnings ratio of -1.95. Aurora Cannabis has a twelve month low of C$2.87 and a twelve month high of C$12.88. The company has a debt-to-equity ratio of 21.20, a quick ratio of 3.13 and a current ratio of 4.92. The company’s 50 day moving average price is C$4.26 and its 200 day moving average price is C$6.03.

Aurora Cannabis (TSE:ACBGet Rating) last issued its quarterly earnings results on Thursday, February 10th. The company reported C($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C($0.21) by C($0.32). The firm had revenue of C$68.42 million for the quarter, compared to analysts’ expectations of C$57.65 million. Equities analysts forecast that Aurora Cannabis will post -0.8 earnings per share for the current fiscal year.

In other news, Senior Officer Andre Jerome sold 6,916 shares of the firm’s stock in a transaction that occurred on Friday, February 18th. The shares were sold at an average price of C$5.31, for a total value of C$36,719.81. Following the transaction, the insider now owns 31,674 shares in the company, valued at C$168,169.94.

About Aurora Cannabis (Get Rating)

Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.

Featured Articles

Analyst Recommendations for Aurora Cannabis (TSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with's FREE daily email newsletter.